Title(s):
Assistant Professor of Oncology
Assistant Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
General Internal Medicine, Lung Cancer
Education and Experience
Training
- Thomas Jefferson University (Philadelphia PA)/ (2000)
Residencies
- The University of Chicago (Chicago IL)/ Internal Medicine (2002)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Hematology/Medical Oncology (2007)
Certifications
- Medical Oncology, American Board of Internal Medicine (2006)
- Internal Medicine, American Board of Internal Medicine (2003)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Physician Title
Assistant Professor of Oncology
Awards and Honors
Young Clinical Scientist Award, Flight Attendant Medical Research Institute, 2007
Pearl M. Stetler Fellowship Award for Women Physicians, Johns Hopkins University, 2006
Young Investigator Award, American Society of Clinical Oncology, 2005
Pearl M. Stetler Fellowship Award for Women Physicians, Johns Hopkins University, 2006
Young Investigator Award, American Society of Clinical Oncology, 2005
Expertise
- General Internal Medicine
- Lung Cancer
Research
Research and Publications
Research Summary:
Dr. Hann is a member of the Upper Aerodigestive Cancer Program, with a primary focus on developing novel therapeutics for lung cancer, particularly small cell lung cancer. As a post-doctoral fellow, her research focused on the preclinical evaluation of a novel small molecule inhibitor which is currently in Phase I/II clinical trials.
She is the recipient of several awards, including an ASCO Young Investigator Award and a FAMRI Young Clinical Scientist Award.
As a faculty member, she sees patients with non-small cell and small cell lung cancer and conducts innovative research with both basic biological and major clinical implications.
Current research projects in the lab include: 1) an evaluation of mechanisms of resistance to a small molecule inhibitor of Bcl-2 currently in clinical trials, 2) a preclinical evaluation of a novel anthracycline in a primary xenograft model of small cell lung cancer, and 3) the development of a small cell lung cancer-specific nanoparticle delivery system for gene therapy.
Trainees in Dr. Hanns lab learn basic molecular biology techniques and approaches to preclinical evaluation of various therapeutic approaches to small cell lung cancer treatment.
Journal Citations:
Hann, C.L.; Brahmer, J.R. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Current treatment options in oncology. 2007 Feb;8(1):28-37.
Hann, C.L.; Rudin, C.M. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in molecular medicine. 2007 Apr;13(4):150-157.
Hann, C.L.; Streiff, M.B. Vena caval filters. In: Kitchens, C.S.; Alving, B.M.; Kessler, C.M., editors. 2nd ed, Consultative Hemostasis and Thrombosis. Philadelphia: Elsevier Press; 2007. p. 531-552.
Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; Rudin, C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-2328.
Hann, C.L.; Rudin, C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008 Nov 30;22(13):1486-1492; discussion 1493-1486, 1498-1500, 1506.
Rudin, C.M.; Hann, C.L.; Peacock, C.D.; Watkins, D.N. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):315-322.
Streiff, M.B.; Hann, C.L. Chapter 12: Inferior Vena Cava Ineterruption. In: Ginsberg, editor, Evidence-Based Hematology: British Medical Journal Publishing Group; 2008.
Gallia, G.L.; Tyler, B.M.; Hann, C.L.; Siu, I.M.; Giranda, V.L.; Vescovi, A.L.; Brem, H.; Riggins, G.J. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Molecular cancer therapeutics. 2009 Feb;8(2):386-393.
Holdhoff, M.; Supko, J.G.; Gallia, G.L.; Hann, C.L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2009 Sep 19;97(2):241-250.
Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; LoRusso, P.M.; Von Hoff, D.D.; de Sauvage, F.J.; Low, J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009 Sep 17;361(12):1173-1178.
Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.
Yauch, R.L.; Dijkgraaf, G.J.; Alicke, B.; Januario, T.; Ahn, C.P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C.A.; Tang, T.; Bazan, J.F.; Kan, Z.; Seshagiri, S.; Hann, C.L.; Gould, S.E.; Low, J.A.; Rudin, C.M.; de Sauvage, F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009 Oct 23;326(5952):572-574.
Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.
Holdhoff, M.; Supko, J.G.; Gallia, G.L.; Hann, C.L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2010 Apr;97(2):241-245.
Dr. Hann is a member of the Upper Aerodigestive Cancer Program, with a primary focus on developing novel therapeutics for lung cancer, particularly small cell lung cancer. As a post-doctoral fellow, her research focused on the preclinical evaluation of a novel small molecule inhibitor which is currently in Phase I/II clinical trials.
She is the recipient of several awards, including an ASCO Young Investigator Award and a FAMRI Young Clinical Scientist Award.
As a faculty member, she sees patients with non-small cell and small cell lung cancer and conducts innovative research with both basic biological and major clinical implications.
Current research projects in the lab include: 1) an evaluation of mechanisms of resistance to a small molecule inhibitor of Bcl-2 currently in clinical trials, 2) a preclinical evaluation of a novel anthracycline in a primary xenograft model of small cell lung cancer, and 3) the development of a small cell lung cancer-specific nanoparticle delivery system for gene therapy.
Trainees in Dr. Hanns lab learn basic molecular biology techniques and approaches to preclinical evaluation of various therapeutic approaches to small cell lung cancer treatment.
Journal Citations:
Hann, C.L.; Brahmer, J.R. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Current treatment options in oncology. 2007 Feb;8(1):28-37.
Hann, C.L.; Rudin, C.M. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in molecular medicine. 2007 Apr;13(4):150-157.
Hann, C.L.; Streiff, M.B. Vena caval filters. In: Kitchens, C.S.; Alving, B.M.; Kessler, C.M., editors. 2nd ed, Consultative Hemostasis and Thrombosis. Philadelphia: Elsevier Press; 2007. p. 531-552.
Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; Rudin, C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-2328.
Hann, C.L.; Rudin, C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008 Nov 30;22(13):1486-1492; discussion 1493-1486, 1498-1500, 1506.
Rudin, C.M.; Hann, C.L.; Peacock, C.D.; Watkins, D.N. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):315-322.
Streiff, M.B.; Hann, C.L. Chapter 12: Inferior Vena Cava Ineterruption. In: Ginsberg, editor, Evidence-Based Hematology: British Medical Journal Publishing Group; 2008.
Gallia, G.L.; Tyler, B.M.; Hann, C.L.; Siu, I.M.; Giranda, V.L.; Vescovi, A.L.; Brem, H.; Riggins, G.J. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Molecular cancer therapeutics. 2009 Feb;8(2):386-393.
Holdhoff, M.; Supko, J.G.; Gallia, G.L.; Hann, C.L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2009 Sep 19;97(2):241-250.
Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; LoRusso, P.M.; Von Hoff, D.D.; de Sauvage, F.J.; Low, J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009 Sep 17;361(12):1173-1178.
Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.
Yauch, R.L.; Dijkgraaf, G.J.; Alicke, B.; Januario, T.; Ahn, C.P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C.A.; Tang, T.; Bazan, J.F.; Kan, Z.; Seshagiri, S.; Hann, C.L.; Gould, S.E.; Low, J.A.; Rudin, C.M.; de Sauvage, F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009 Oct 23;326(5952):572-574.
Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.
Holdhoff, M.; Supko, J.G.; Gallia, G.L.; Hann, C.L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2010 Apr;97(2):241-245.
Research Interests
- Small cell and non-small cell lung cancer
- New drug development for lung cancer
More Info
Languages
- English
Memberships
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Clinical Oncology
Clinical Trials
- lung cancer
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts